Oil of eucalyptus
CAS 8000-48-4
Oil of eucalyptus (CAS 8000-48-4) is a pharmaceutical compound with 0 bioactivity targets and 26 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Oil of eucalyptus is linked to DTXSID9034781 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Oil of eucalyptus used for in pharmaceutical contexts?
Oil of eucalyptus (CAS 8000-48-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Oil of eucalyptus?
Oil of eucalyptus has 26 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Atrial fibrillation, Brain natriuretic peptide increased, Bronchospasm, Cardiac disorder, Chest discomfort. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Oil of eucalyptus also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Eucalyptus Oil (Eucalyptus Globulus Leaf Oil) with EU status "restricted".
What clinical phase is Oil of eucalyptus in?
No phase 1-4 clinical development badge is rendered for Oil of eucalyptus because the matched compound identifier rows do not contain a max-phase value.